Bharat Book Bureau Provides the Trending Market Research Report on “Biosimilars Market by Product (Monoclonal antibodies (infliximab, rituximab, trastuzumab), Insulin, Interferon, Etanercept, Glucagon, Calcitonin), Indication (Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease), Region – Global Forecast to 2026” under healthcare market research report Category. The report offers a collection of superior market research, market analysis, analysis, competitive intelligence and Market reports.
The global Biosimilars Market is projected to reach USD 44.7 billion by 2026 from USD 15.6 billion in 2021, at a CAGR of 23.5% during the forecast period of 2021 to 2026. Market growth is largely driven by the rising incidence of chronic diseases and increasing demand of biosimilars for their cost-effectiveness. Regulatory approvals and other regulations favoring biosimilars adoption in different countries is also a major driving factor in the biosimilars market. However, the complexities in the development and manufacturing of biosimilars and resistance from reference biologic manufacturers is expected to restrain the growth of this market during the forecast period.
“The monoclonal antibodies product segment accounted for the highest growth rate in the biosimilars market, byproduct, during the forecast period”
In 2020, the monoclonal antibodies product segment accounted for the largest share (27.5%) of the biosimilars market, mainly due to the low prices of biosimilar monoclonal antibodies compared to the reference drugs and their wide use in the treatment of cancer, autoimmune disorders, and osteoporosis. They are also used in indications such as rheumatoid arthritis, multiple sclerosis, and macular degeneration. The growth of the fastest-growing segment was attributed to the rising incidence of cancer cases and chronic diseases and growth in the geriatric population.
“Oncology segment accounted for the largest share of the indication segment”
Based on the indication, the biosimilars market is segmented into oncology, inflammatory and autoimmune diseases, chronic diseases, blood disorders, growth hormone deficiency, infectious diseases, and other indications (infertility, hypoglycemia, myocardial infarction, postmenopausal osteoporosis, chronic kidney failure, and ophthalmic diseases). Oncology is the largest segment in this market owing to the availability of biosimilars at a lower price than innovative biologics and a large number of cancer patients. The availability of biosimilars in the field of oncology has lowered prices and made cancer treatment more affordable and accessible. Also, due to the high incidence and prevalence of cancer, healthcare systems across the globe are focusing on reducing the burden of cancer by adopting cost effective treatment options. In this scenario, biosimilar drugs might witness widespread adoption in major markets such as the US, Europe, and the Asia Pacific. Considering these factors and the upending competition from biosimilars, many major biologic
pharmaceutical companies are making significant investments in the development and approval of biosimilar drugs.
“Asia Pacific: The fastest-growing region in the biosimilars market”
The biosimilars market is segmented into Europe, Asia Pacific, North America, latin America and Middle East and Africa. The APAC market, on the other hand, is expected to be the fastest-growing regional segment during the forecast period due to the presence of many emerging players, less-stringent regulations, and increasing cooperation among leading and regional players for development, manufacture and commercialization of biosimilars.
The primary interviews conducted for this report can be categorized as follows:
By Respondent: Supply Side- 80%and Demand Side 20%
By Designation: Managers - 55%, CXOs - 20%, and Executives - 25%
By Region: North America -50%, Europe -20%, Asia-Pacific -20%, RoW -10%
Lists of Companies Profiled in the Report:
Novartis AG (Switzerland)
Pfizer, Inc. (US)
Dr. Reddy’s Laboratories Ltd (India)
Amgen, Inc. (US)
Eli Lilly and Company (US)
Teva Pharmaceutical Industries Ltd. (Israel)
Fresenius SE & Co. KGaA (Germany)
STADA Arzneimittel AG (Germany)
Boehringer Ingelheim (Germany)
Gedeon Richter PLC (Hungary)
Celltrion (South Korea)
Samsung Biologics (South Korea)
Biocon Limited (India)
Viatris, Inc. (US)
Amega Biotech (Argentina)
Apotex, Inc. (Canada)
Probiomed S.A. De C.V. (Mexico)
Fujifilm Kyowa Kirin Biologics Co., Ltd. (Japan)
Intas Pharmaceuticals Ltd. (India)
Reliance Life Sciences (India)
Kashiv Biosciences (US)
This report provides a detailed picture of the biosimilars market. It aims at estimating the size and future growth potential of the market across different segments such as the product,indication and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall biosimilars market and its sub segments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, challenges and opportunities.
Browse our full report with Table of Content :
About Bharat Book Bureau:
Bharat Book is Your One-Stop-Shop with an exhaustive coverage of 4,80,000 reports and insights that includes latest Market Study, Market Trends & Analysis, Forecasts Customized Intelligence, Newsletters and Online Databases. Overall a comprehensive coverage of major industries with a further segmentation of 100+ subsectors.
Contact us at:
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Email: [email protected]